Home ›
Head and Neck Cancer Trials ›
NCT06005324
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
Trial Details
NCT ID NCT06005324
Phase PHASE1
Sponsor University of Chicago
Status RECRUITING
Cancer Type Head and Neck Cancer
Interventions Paclitaxel Carboplatin Cetuximab Standard Dose Radiation Low Dose Radiation Cisplatin
Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005
Key Eligibility Criteria
Patients must have pathologically confirmed locally advanced, non-metastatic, human papillomavirus (HPV) negative head and neck squamous cell carci… Stage III or IV disease based on American Joint Committee on Cancer (AJCC) staging 8th edition. If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry. Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment o…
For full eligibility, visit ClinicalTrials.gov .